

AD _____

Award Number: DAMD17-98-1-8582

TITLE: Genistein Programming against Prostate Cancer

PRINCIPAL INVESTIGATOR: Coral A. Lamartiniere, Ph.D.

CONTRACTING ORGANIZATION: University of Alabama at Birmingham
Birmingham, Alabama 35294-3300

REPORT DATE: September 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010122 085

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE September 1999	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 98 - 30 Aug 99)
----------------------------------	----------------------------------	---

4. TITLE AND SUBTITLE Genistein Programming Against Prostate Cancer	5. FUNDING NUMBERS DAMD17-98-1-8582
--	--

6. AUTHOR(S) Coral A. Lamartiniere, Ph.D.
--

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Alabama at Birmingham Birmingham, Alabama 35294-3300	8. PERFORMING ORGANIZATION REPORT NUMBER
---	--

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012	10. SPONSORING / MONITORING AGENCY REPORT NUMBER
---	--

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited	12b. DISTRIBUTION CODE
--	------------------------

13. ABSTRACT (Maximum 200 Words)

The purpose of this research is to develop a rodent prostate cancer model and to investigate the potential of genistein to suppress the development of this cancer. We have hypothesized that exposure to genistein, a component of soy, during early critical periods of development will modulate development of hormone responsive target organs and cell differentiation. We further hypothesized that these developmental modifications set the program for later response to hormonally-active effectors. We believe that programming events play a significant role in determining susceptibility for prostate cancer. Starting at conception, rats were exposed to 0, 25- and 250 mg genistein/kg AIN-76A diet. Seven week old male offspring were injected orthotopically into the dorsolateral prostate with the carcinogen, N-methylnitrosurea (NMU), for the induction of adenocarcinomas which takes 12 months. Animals are being palpated on a weekly basis for tumors (to be continued in the second year). Also, we have measured, in 187 day old rats exposed \pm genistein and to NMU, biomarkers in the dorsolateral prostate. mRNA and protein levels of EGF-receptor and androgen receptor were not altered. Understanding the in vivo mechanism of genistein action should allow soy, genistein, or potent genistein analogues to be used against prostate cancer in humans.

14. SUBJECT TERMS Prostate Cancer, genistein, prevention	15. NUMBER OF PAGES 10
	16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited
---	--	---	---

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

Date

8/26/99

Table of Contents

Cover Page	1
Standard Form 298	2
Foreword	3
Table of Contents	4
Introduction	5
Body	5
Key Research Accomplishments	5
Reportable Outcomes/Conclusions	5
References	5
Appendices	6

Introduction

The purpose of this research is to develop a rodent prostate cancer model and to investigate the potential of genistein to suppress the development of this cancer. We have hypothesized that exposure to genistein, a component of soy, during early critical periods of development would modulate development of hormone responsive target organs and cell differentiation. We further hypothesized that these developmental modifications set the program for later response to hormonally-active effectors. We believe that programming events play a significant role in determining susceptibility for prostate cancer. Our specific aims are: 1) to investigate the potential of life-time exposure (including perinatal) to genistein in the diet to imprint for reduced susceptibility for prostate cancer, 2) to determine if life-time exposure to genistein in the diet will down-regulate EGF receptor levels in prostates of adult rats and 3) to determine the concentrations of genistein and its metabolites in blood and dorsolateral prostates of male offspring fed genistein in the diet. Understanding the in vivo mechanism of genistein action will allow soy, genistein, or potent genistein analogues to be used against prostate cancer in humans.

Body

Task 1) To determine if life-time genistein in the diet protects against chemically-induced prostate cancer (years 1 and 2). Virgin female Sprague Dawley-CD rats were purchased and fed either 0, 25 mg, or 250 mg genistein/kg AIN-76A diet from 2 weeks prior to initiation of breeding, until offspring are killed. At 70 days postpartum, the carcinogen, MNU, was injected into the prostate. These animals continue to be palpated for prostate tumors. It takes 12 months for the tumors to develop.

This specific aim has been complicated by the aggressive behavior of these animals, resulting in having to house these rats 1/cage. Hence, the cost of animal housing has escalated (3x).

Task 2) From the dorsolateral prostates of rats exposed \pm genistein we will investigate the expression of the EGF-receptor (year 1). In 117 day old rats exposed to NMU, \pm genistein, no difference in mRNA and protein levels of EGF-receptor and androgen receptor was found. We will also measure mRNA levels of estrogen receptors-alpha and beta.

Task 3) To determine the concentrations of genistein and its metabolites in blood and dorsolateral prostates of male offspring fed genistein in the diet. Feed consumption and isoflavone content of the diets will be determined. This will provide data on bioavailability. Identification and quantitation will be done by H.P.L.C.-mass spectrometry. This will be done in the second year.

Key Research Accomplishments

The NMU rat prostate cancer model has been initiated and two groups on genistein have been set up to investigate chemoprevention. Life-time exposure to genistein does not alter mRNA and protein levels of EGF-receptor and androgen receptor.

Reportable Outcomes/Conclusions

In this model system dietary genistein does not modulate the EGF-receptor or the androgen receptor. Since the tumor study is a development study, we do not yet have any significant reportable outcomes or conclusions.


References

Not applicable.


Appendices

Four Figures

EGF-receptor mRNA Expression in Rat Dorsolateral Prostate




EGF-receptor mRNA levels in dorsolateral prostates of Lobund-Wistar rats fed genistein in the diet from conception through day 187. At day 70 postpartum, all rats were injected with 42 mg N-methylnitrosourea/kg body weight into the dorsolateral prostate. All animals received silastic implants of testosterone (2 cm x 0.2 cm) every 12 weeks. Rats received either zero, 25 mg genistein, or 250 mg genistein/kg AIN-76A diet. RNA from the dorsolateral prostate was isolated, reverse transcribed and amplified. PCR products for the EGF-receptor were verified by Southern blots with oligonucleotide probes. Detection of fluorescent signal was analyzed by densitometry. The data have been expressed as a percentage of mRNA level of the controls. Each group contained 6 samples, each from different rats. No statistical significance was detected between treated groups and controls.




EGF-receptor levels in dorsolateral prostates of Lobund-Wistar rats fed genistein in the diet from conception through day 187. At day 70 postpartum, all rats were injected with 42 mg N-methylnitrosourea/kg body weight into the dorsolateral prostate. All animals received silastic implants of testosterone (2 cm x 0.2 cm) every 12 weeks. Rats received either zero, 25 mg genistein, or 250 mg genistein/kg AIN-76A diet. Tissue lysates were electrophoresed, blotted, and probed with an antibody against the EGF-receptor. Densitometric values of controls were set at 100. The data have been expressed as a percentage of the controls. Each group contained a minimum of 6 samples, each from different rats. No statistical significance was detected between treated groups and controls.

Androgen Receptor mRNA expression in Rat Dorsolateral Prostate



Androgen receptor mRNA levels in dorsolateral prostates of Lobund-Wistar rats fed genistein in the diet from conception through day 187. At day 70 postpartum, all rats were injected with 42 mg N-methylnitrosourea/kg body weight into the dorsolateral prostate. All animals received silastic implants of testosterone (2 cm x 0.2 cm) every 12 weeks. Rats received either zero, 25 mg genistein, or 250 mg genistein/kg AIN-76A diet. RNA from dorsolateral prostate was isolated, reverse transcribed and amplified. PCR products for the androgen receptor were verified by Southern blots with oligonucleotide probes. Detection of fluorescent signal was analyzed by densitometry. The data have been expressed as a percentage of mRNA level of the controls. Each group contained 6 samples, each from different rats. No statistical significance was detected between treated groups and controls.



Androgen receptor levels in dorsolateral prostates of Lobund-Wistar rats fed genistein in the diet from conception through day 187. At day 70 postpartum, all rats were injected with 42 mg N-methylnitrosourea/kg body weight into the dorsolateral prostate. All animals received silastic implants of testosterone (2 cm x 0.2 cm) every 12 weeks. Rats received either zero, 25 mg genistein, or 250 mg genistein/kg AIN-76A diet. Tissue lysates were electrophoresed, blotted, and probed with an antibody against the androgen receptor. Densitometric values of controls were set at 100. The data have been expressed as a percentage of the controls. Each group contained a minimum of 6 samples, each from different rats. No statistical significance was detected between treated groups and controls.